ClinicalTrials.gg
CompletedNCT00812968Updated Nov 19, 2019Results posted

Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.

A Phase 2 interventional study of Lenalidomide in Myelodysplastic Syndromes, sponsored by Celgene. Completed at 6 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Sep 2007, registered Dec 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing lenalidomide in Myelodysplastic Syndromes — none open to participants now, none under way, none of them phase 3. Lenalidomide · Myelodysplastic Syndromes.

Enrollment
33rd of 43
11 · median 32
Started
2007
the only one that year
Phase 2
24 of 44
none open now
Registered
12th of 44
by date
Lead sponsor
4 of 44
Celgene

Among the 44 studies testing lenalidomide in Myelodysplastic Syndromes, this one is the 33rd largest by enrollment of the 43 interventional ones that give a count, is the only one that started in 2007, is one of 24 in phase 2, and was the 12th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

None of the 44 studies testing lenalidomide in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing lenalidomide in Myelodysplastic Syndromes as a file.
02

Study summary

The purpose of this clinical experience study is to determine whether CC-5013 is safe and effective (to include studying the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body [pharmacokinetics]) in Japanese subjects with low- or intermediate-1-risk MDS (IPSS risk categories) associated with a deletion 5(q31-33) abnormality and symptomatic anemia.

03

Conditions studied

  • Myelodysplastic Syndromes

Keywords

  • Myelodysplastic Syndromes
  • Lenalidomide
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must understand and voluntarily sign an form.
  • Age ≥ 20 years at the time of signing the informed consent form.
  • Must be able to adhere to the study visit schedule and other protocol requirements.
  • Diagnosis of Myelodysplastic Syndrome (MDS) that meets International Prognostic Scoring System (IPSS) criteria for low- or intermediate-1-risk disease associated with a deletion 5(q31-33) abnormality
  • Symptomatic anemia secondary to MDS defined as:Untransfused level \< 10.0 g/dL and a Functional Assessment of Cancer Therapy (FACT)-anemia subscale score of ≤ 74 or Transfusion dependent anemia

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females.
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  • Prior therapy with lenalidomide.
  • Patients with any of the following laboratory abnormalities within 14 days of starting study drug: (ANC) \< 750 cells/μL (0.75 x 10\^9/L) count \< 50,000/μL (50x10\^9/L) Serum creatinine > 2.5 mg/dL (AST) or Alanine Aminotransferase (ALT) > 3.0 x (ULN)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Lenalidomide

    Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).

    Drug: Lenalidomide

Interventions

  • Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).

    Also known as: CC-5013

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AE)

    An AE that resulted in any of the following outcomes was defined as a serious adverse event (SAE): * Death; * Life-threatening event; * Any inpatient hospitalization or prolongation of existing hospitalization; * Persistent or significant disability or incapacity; * Congenital anomaly or birth defect; * Any other important medical event. The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 3.0) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death.

    Time frame: After the first study dose until 28 days after completion of/discontinuation from the study (maximum time on study was 155 weeks).

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Lenalidomide

    Maximum observed plasma concentration of lenalidomide after a single dose on Day and after multiple doses (Day 4).

    Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.

  2. Time to Maximum Plasma Concentration (Tmax) of Lenalidomide

    Time to maximum observed plasma concentration of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).

    Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.

  3. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Lenalidomide

    Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUCt) of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).

    Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.

  4. Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Lenalidomide

    Area under the plasma concentration-time curve over the dosing interval (AUCτ) of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).

    Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12 and 24 hours post-dose.

  5. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Lenalidomide

    Area under the plasma concentration-time curve from time zero to infinity (AUC∞) of lenalidomide after a single dose on Day 1.

    Time frame: Day 1 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12 and 24 hours post-dose.

  6. Terminal Half-life (T1/2) of Lenalidomide

    The apparent terminal half-life is the time required for plasma concentration to decrease by 50% after pseudo-equilibrium of distribution has been reached, and calculated as the natural logarithm of 2 (0.693) / Apparent terminal rate constant (λz).

    Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.

  7. Apparent Volume of Distribution (VzF) of Lenalidomide

    Apparent volume of distribution of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).

    Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.

  8. Apparent Total Plasma Clearance (CL/F) of Lenalidomide

    Apparent total plasma clearance (CL/F) of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).

    Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.

  9. Apparent Terminal Elimination Rate Constant of Lenalidomide

    Apparent terminal elimination rate constant of lenalidomide determined after a single dose on Day 1 and multiple doses (Day 4).

    Time frame: Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.

  10. Number of Participants With a Erythroid Response

    Erythroid response was determined using the International Working Group (IWG) 2000 criteria, categorized as a major response or minor response. A major response in patients with transfusion-dependent anemia (receiving ≥ 4.5 units of red blood cell (RBC) transfusion during 56 consecutive days at Baseline) is defined as RBC transfusion independence accompanied by a ≥1.0 g/dL increase from Baseline in hemoglobin sustained for 56 days consecutively during the treatment period. In patients with transfusion-independent anemia with hemoglobin \< 10 g/dL at Baseline a major response is defined as a \> 2.0 g/dL increase from Baseline in hemoglobin sustained for consecutive 56 days. Minor response in patients with transfusion-dependent anemia defined as ≥ 50% decrease from Baseline in transfusion requirements sustained for consecutive 56 days, and in transfusion-independent patients as 1.0 to 2.0 g/dL increase from Baseline in hemoglobin sustained for consecutive 56 days.

    Time frame: Response was assessed every 28 days through Week 156.

  11. Time to Erythroid Response

    Time to erythroid response was calculated as the time from the first dose of study drug to the start of the first major or minor erythroid response. Similarly, time to major erythroid response was calculated as the time from the first dose of study drug to the start of the first major erythroid response.

    Time frame: From the first dose of study drug through Week 156

  12. Duration of Erythroid Response

    Duration of erythroid response was calculated as the time from the start of the first major or minor erythroid response to the end of the response. Similarly, duration of major erythroid response was calculated as the time from the start of the first major erythroid response to the end of the response. Response duration was censored at the last adequate assessment for patients who maintained response.

    Time frame: From the first dose of study drug through Week 156

  13. Change From Baseline in Hemoglobin Concentration

    Change in hemoglobin concentration from Baseline to the maximum observed value during the major erythroid response period for major erythroid responders.

    Time frame: Baseline and from Day1 until the maximum observed value (up to 155 weeks)

  14. Number of Participants With a Neutrophil Response

    Neutrophil response was determined using the IWG (2000) criteria. A major response for participants with a Baseline neutrophil count \< 1,500/mm\^3 is defined as a ≥ 100% increase or a ≥ 500/mm\^3 increase, whichever is greater, sustained for consecutive 56 days during the treatment period. A minor response for participants with a Baseline neutrophil count \< 1,500/mm\^3 is defined as a ≥ 100% increase, but an absolute increase \< 500/mm\^3, sustained for consecutive 56 days during the treatment period.

    Time frame: Response was assessed every 28 days through Week 156

  15. Number of Participants With a Platelet Response

    Platelet response was determined using the IWG (2000) criteria. Major response in patients with Baseline platelet count \< 100,000/mm\^3 is defined as a ≥ 30,000/mm\^3 increase sustained for consecutive 56 days during the treatment period. In platelet-transfusion-dependent patients at Baseline a major response is defined as stabilization of platelet counts and platelet transfusion independence sustained for consecutive 56 days during the treatment period. Minor response in patients with Baseline platelet count \< 100,000/mm\^3 is defined as a ≥ 50% increase in platelet count with an absolute increase \> 10,000/mm\^3 and \< 30,000/mm\^3 sustained for consecutive 56 days during the treatment period.

    Time frame: Response was assessed every 28 days through Week 156

  16. Number of Participants With a Cytogenetic Response

    Cytogenetic (chromosome structure) abnormalities were assessed by a central cytogenetic reviewer based on prints and cytogenetic reports of the bone marrow sample from the central laboratory. Cytogenetic response was determined using the IWG (2000) criteria and categorized as either a major response or minor response. Twenty metaphases were analyzed for the determination of cytogenetic response. A major response was defined as no detectable cytogenetic abnormality, if an abnormality was present at Baseline, sustained for consecutive 56 days during the treatment period. A minor response was defined as ≥ 50% reduction from Baseline in abnormal metaphases sustained for consecutive 56 days during the treatment period.

    Time frame: Response was assessed every 12 weeks through Week 156

  17. Change From Baseline in Percentage of Bone Marrow Erythroblasts

    Bone marrow morphology was assessed by the central hematologic reviewers based on the locally-prepared bone marrow smear slide and clot section.

    Time frame: Baseline, at the end of Cycle 3 (Day 85) and Cycle 6 (Day 169).

  18. Percentage of Bone Marrow Myeloblasts

    Bone marrow morphology was assessed by the central hematologic reviewers based on the locally-prepared bone marrow smear slide and clot section.

    Time frame: Baseline, at the end of Cycle 3 (Day 85) and Cycle 6 (Day 169).

  19. Percentage of Bone Marrow Promyelocytes

    Bone marrow morphology was assessed by the central hematologic reviewers based on the locally-prepared bone marrow smear slide and clot section.

    Time frame: Baseline, at the end of Cycle 3 (Day 85) and Cycle 6 (Day 169).

07

Results

Posted Dec 17, 2013

Participant flow

Participant flow — Overall Study
MilestoneLenalidomide
Started11
Completed0
Not completed11
Withdrew: Relapse after erythroid response6
Withdrew: Disease progression1
Withdrew: No further treatment required1
Withdrew: Study closed due to marketing approval3

Outcome measures

PrimaryNumber of Participants With Adverse Events (AE)

An AE that resulted in any of the following outcomes was defined as a serious adverse event (SAE): * Death; * Life-threatening event; * Any inpatient hospitalization or prolongation of existing hospitalization; * Persistent or significant disability or incapacity; * Congenital anomaly or birth defect; * Any other important medical event. The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 3.0) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death.

Time frame:
After the first study dose until 28 days after completion of/discontinuation from the study (maximum time on study was 155 weeks).
Reported as:
Number · participants
Number of Participants With Adverse Events (AE)
participantsLenalidomide
Any adverse event (AE)11
AE related to study drug11
Grade 3 or 4 AE11
Grade 3 or 4 AE related to study drug11
Serious AE (SAE)3
SAE related to study drug1
AE leading to discontinuation of study drug0
Related AE leading to discontinuation0
AE leading to a dose reduction or interruption10
Related AE leading to dose reduction/interruption9
Deaths0
SecondaryMaximum Observed Plasma Concentration (Cmax) of Lenalidomide

Maximum observed plasma concentration of lenalidomide after a single dose on Day and after multiple doses (Day 4).

Time frame:
Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Lenalidomide
ng/mLLenalidomide: Day 1Lenalidomide: Day 4
Maximum Observed Plasma Concentration (Cmax) of Lenalidomide136 ± 43.1149 ± 31.2
SecondaryTime to Maximum Plasma Concentration (Tmax) of Lenalidomide

Time to maximum observed plasma concentration of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).

Time frame:
Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of Lenalidomide
hoursLenalidomide: Day 1Lenalidomide: Day 4
Time to Maximum Plasma Concentration (Tmax) of Lenalidomide2.52 (1.00 to 5.95)2.93 (1.00 to 4.00)
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Lenalidomide

Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUCt) of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).

Time frame:
Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Lenalidomide
ng*h/mLLenalidomide: Day 1Lenalidomide: Day 4
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUCt) of Lenalidomide718.4 ± 41.2803.5 ± 46.9
SecondaryArea Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Lenalidomide

Area under the plasma concentration-time curve over the dosing interval (AUCτ) of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).

Time frame:
Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12 and 24 hours post-dose.
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Lenalidomide
ng*h/mLLenalidomide: Day 1Lenalidomide: Day 4
Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Lenalidomide866.5 ± 44.1877.9 ± 43.0
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Lenalidomide

Area under the plasma concentration-time curve from time zero to infinity (AUC∞) of lenalidomide after a single dose on Day 1.

Time frame:
Day 1 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12 and 24 hours post-dose.
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Lenalidomide
ng*h/mLLenalidomide
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of Lenalidomide878.0 ± 45.1
SecondaryTerminal Half-life (T1/2) of Lenalidomide

The apparent terminal half-life is the time required for plasma concentration to decrease by 50% after pseudo-equilibrium of distribution has been reached, and calculated as the natural logarithm of 2 (0.693) / Apparent terminal rate constant (λz).

Time frame:
Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.
Reported as:
Geometric mean · hours
Terminal Half-life (T1/2) of Lenalidomide
hoursLenalidomide: Day 1Lenalidomide: Day 4
Terminal Half-life (T1/2) of Lenalidomide3.26 ± 23.03.57 ± 29.6
SecondaryApparent Volume of Distribution (VzF) of Lenalidomide

Apparent volume of distribution of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).

Time frame:
Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.
Reported as:
Geometric mean · liters
Apparent Volume of Distribution (VzF) of Lenalidomide
litersLenalidomide: Day 1Lenalidomide: Day 4
Apparent Volume of Distribution (VzF) of Lenalidomide53.6 ± 30.958.6 ± 25.8
SecondaryApparent Total Plasma Clearance (CL/F) of Lenalidomide

Apparent total plasma clearance (CL/F) of lenalidomide after a single dose on Day 1 and multiple doses (Day 4).

Time frame:
Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.
Reported as:
Geometric mean · mL/minute
Apparent Total Plasma Clearance (CL/F) of Lenalidomide
mL/minuteLenalidomide: Day 1Lenalidomide: Day 4
Apparent Total Plasma Clearance (CL/F) of Lenalidomide189.8 ± 45.1189.9 ± 43.0
SecondaryApparent Terminal Elimination Rate Constant of Lenalidomide

Apparent terminal elimination rate constant of lenalidomide determined after a single dose on Day 1 and multiple doses (Day 4).

Time frame:
Days 1 and 4 at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose.
Reported as:
Geometric mean · 1/h
Apparent Terminal Elimination Rate Constant of Lenalidomide
1/hLenalidomide: Day 1Lenalidomide: Day 4
Apparent Terminal Elimination Rate Constant of Lenalidomide0.213 ± 23.00.194 ± 39.0
SecondaryNumber of Participants With a Erythroid Response

Erythroid response was determined using the International Working Group (IWG) 2000 criteria, categorized as a major response or minor response. A major response in patients with transfusion-dependent anemia (receiving ≥ 4.5 units of red blood cell (RBC) transfusion during 56 consecutive days at Baseline) is defined as RBC transfusion independence accompanied by a ≥1.0 g/dL increase from Baseline in hemoglobin sustained for 56 days consecutively during the treatment period. In patients with transfusion-independent anemia with hemoglobin \< 10 g/dL at Baseline a major response is defined as a \> 2.0 g/dL increase from Baseline in hemoglobin sustained for consecutive 56 days. Minor response in patients with transfusion-dependent anemia defined as ≥ 50% decrease from Baseline in transfusion requirements sustained for consecutive 56 days, and in transfusion-independent patients as 1.0 to 2.0 g/dL increase from Baseline in hemoglobin sustained for consecutive 56 days.

Time frame:
Response was assessed every 28 days through Week 156.
Reported as:
Number · participants
Number of Participants With a Erythroid Response
participantsLenalidomide
Erythroid responders (major or minor)11
Major erythroid responders11
SecondaryTime to Erythroid Response

Time to erythroid response was calculated as the time from the first dose of study drug to the start of the first major or minor erythroid response. Similarly, time to major erythroid response was calculated as the time from the first dose of study drug to the start of the first major erythroid response.

Time frame:
From the first dose of study drug through Week 156
Reported as:
Median · weeks
Time to Erythroid Response
weeksLenalidomide
Time to erythroid response (major or minor)2.1 (0.3 to 11.1)
Time to major erythroid response6.3 (3.1 to 31.1)
SecondaryDuration of Erythroid Response

Duration of erythroid response was calculated as the time from the start of the first major or minor erythroid response to the end of the response. Similarly, duration of major erythroid response was calculated as the time from the start of the first major erythroid response to the end of the response. Response duration was censored at the last adequate assessment for patients who maintained response.

Time frame:
From the first dose of study drug through Week 156
Reported as:
Median · weeks
Duration of Erythroid Response
weeksLenalidomide
Duration of erythroid response (major or minor)76.6 (8.9 to 152.0)
Duration of major erythroid response72.1 (32.1 to 144.1)
SecondaryChange From Baseline in Hemoglobin Concentration

Change in hemoglobin concentration from Baseline to the maximum observed value during the major erythroid response period for major erythroid responders.

Time frame:
Baseline and from Day1 until the maximum observed value (up to 155 weeks)
Reported as:
Median · g/dL
Change From Baseline in Hemoglobin Concentration
g/dLLenalidomide
Baseline concentration7.0 (4.7 to 9.1)
Maximum concentration during study13.1 (10.7 to 15.8)
Change from Baseline to maximum value6.0 (2.7 to 11.1)
SecondaryNumber of Participants With a Neutrophil Response

Neutrophil response was determined using the IWG (2000) criteria. A major response for participants with a Baseline neutrophil count \< 1,500/mm\^3 is defined as a ≥ 100% increase or a ≥ 500/mm\^3 increase, whichever is greater, sustained for consecutive 56 days during the treatment period. A minor response for participants with a Baseline neutrophil count \< 1,500/mm\^3 is defined as a ≥ 100% increase, but an absolute increase \< 500/mm\^3, sustained for consecutive 56 days during the treatment period.

Time frame:
Response was assessed every 28 days through Week 156
Reported as:
Number · participants
Number of Participants With a Neutrophil Response
participantsLenalidomide
Major response1
Minor response0
SecondaryNumber of Participants With a Platelet Response

Platelet response was determined using the IWG (2000) criteria. Major response in patients with Baseline platelet count \< 100,000/mm\^3 is defined as a ≥ 30,000/mm\^3 increase sustained for consecutive 56 days during the treatment period. In platelet-transfusion-dependent patients at Baseline a major response is defined as stabilization of platelet counts and platelet transfusion independence sustained for consecutive 56 days during the treatment period. Minor response in patients with Baseline platelet count \< 100,000/mm\^3 is defined as a ≥ 50% increase in platelet count with an absolute increase \> 10,000/mm\^3 and \< 30,000/mm\^3 sustained for consecutive 56 days during the treatment period.

Time frame:
Response was assessed every 28 days through Week 156

No measurements were reported for this outcome.

SecondaryNumber of Participants With a Cytogenetic Response

Cytogenetic (chromosome structure) abnormalities were assessed by a central cytogenetic reviewer based on prints and cytogenetic reports of the bone marrow sample from the central laboratory. Cytogenetic response was determined using the IWG (2000) criteria and categorized as either a major response or minor response. Twenty metaphases were analyzed for the determination of cytogenetic response. A major response was defined as no detectable cytogenetic abnormality, if an abnormality was present at Baseline, sustained for consecutive 56 days during the treatment period. A minor response was defined as ≥ 50% reduction from Baseline in abnormal metaphases sustained for consecutive 56 days during the treatment period.

Time frame:
Response was assessed every 12 weeks through Week 156
Reported as:
Number · participants
Number of Participants With a Cytogenetic Response
participantsLenalidomide
Major response1
Minor response5
SecondaryChange From Baseline in Percentage of Bone Marrow Erythroblasts

Bone marrow morphology was assessed by the central hematologic reviewers based on the locally-prepared bone marrow smear slide and clot section.

Time frame:
Baseline, at the end of Cycle 3 (Day 85) and Cycle 6 (Day 169).
Reported as:
Median · Percentage of Bone Marrow Erythroblasts
Change From Baseline in Percentage of Bone Marrow Erythroblasts
Percentage of Bone Marrow ErythroblastsLenalidomide
Change from Baseline at the end of Cycle 336.5 (-12.0 to 51.0)
Change from Baseline at the end of Cycle 621.5 (-5.0 to 56.0)
SecondaryPercentage of Bone Marrow Myeloblasts

Bone marrow morphology was assessed by the central hematologic reviewers based on the locally-prepared bone marrow smear slide and clot section.

Time frame:
Baseline, at the end of Cycle 3 (Day 85) and Cycle 6 (Day 169).
Reported as:
Median · Percentage of myeloblasts
Percentage of Bone Marrow Myeloblasts
Percentage of myeloblastsLenalidomide
Baseline (N=11)3.77 (1.20 to 8.40)
End of Cycle 3 (N=10)1.47 (0.01 to 4.55)
End of Cycle 6 (N=10)1.79 (0.01 to 4.00)
SecondaryPercentage of Bone Marrow Promyelocytes

Bone marrow morphology was assessed by the central hematologic reviewers based on the locally-prepared bone marrow smear slide and clot section.

Time frame:
Baseline, at the end of Cycle 3 (Day 85) and Cycle 6 (Day 169).
Reported as:
Median · Percentage of promyelocytes
Percentage of Bone Marrow Promyelocytes
Percentage of promyelocytesLenalidomide
Baseline (N=11)5 (0 to 13)
End of Cycle 3 (N=10)5 (1 to 12)
End of Cycle 6 (N=10)5 (1 to 12)

Adverse events

Collected over From the first dose of study drug through 28 days after completion of/discontinuation from the study (maximum time on study was 155 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide—3/11 (27.3%)11/11 (100%)
Most frequent serious events
Most frequent serious events
EventLenalidomide
Gastric UlcerGastrointestinal disorders1/11
CholelithiasisHepatobiliary disorders1/11
Herpes ZosterInfections and infestations1/11
InfluenzaInfections and infestations1/11
Spinal Compression FractureInjury, poisoning and procedural complications1/11
Liver Function Test AbnormalInvestigations1/11
AnorexiaMetabolism and nutrition disorders1/11
Most frequent other events
Showing 10 of 108
Most frequent other events
EventLenalidomide
NeutropeniaBlood and lymphatic system disorders11/11
ThrombocytopeniaBlood and lymphatic system disorders11/11
LeukopeniaBlood and lymphatic system disorders10/11
ConstipationGastrointestinal disorders10/11
LymphopeniaBlood and lymphatic system disorders8/11
NasopharyngitisInfections and infestations8/11
RashSkin and subcutaneous tissue disorders8/11
EosinophiliaBlood and lymphatic system disorders5/11
PruritusSkin and subcutaneous tissue disorders5/11
BasophiliaBlood and lymphatic system disorders4/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lenalidomide
Mean71.8 ± 5.95
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide
Female7
Male4
Region of Enrollment
Region of Enrollment(participants)Lenalidomide
Japan11
Duration of MDS
Duration of MDS(years)Lenalidomide
Mean2.0 ± 1.44
International Prognostic Scoring System (IPSS) Score
International Prognostic Scoring System (IPSS) Score(participants)Lenalidomide
Low risk2
Intermediate-1 risk9
Intermediate-2 risk0
High risk0
French-American-British (FAB) classification of MDS
French-American-British (FAB) classification of MDS(participants)Lenalidomide
Refractory anemia (RA)9
Refractory anemia with ringed sideroblasts (RARS)0
Refractory anemia with excess blasts (RAEB)2
Chronic myelomonocytic leukemia (CMML)0
RAEB in transformation (RAEB-t)0
World Health Organization Classification of MDS
World Health Organization Classification of MDS(participants)Lenalidomide
Refractory anemia (RA)0
RA with ringed sideroblasts (RARS)0
Refractory anemia with excess blasts-1 (RAEB-1)2
Refractory anemia with excess blasts-2 (RAEB-2)0
Refractory cytopenia multilineage dysplasia (RCMD)1
RCMD and ringed sideroblasts (RCMD-RS)0
MDS, unclassified (MDS-U)0
MDS associated with isolated del(5q)8
Bone Marrow Cellularity
Bone Marrow Cellularity(participants)Lenalidomide
Aplastic (0%)0
Hypocellular (> 0% to ≤ 30%)3
Normocellular (> 30% to ≤ 60%)5
Hypercellular (> 60% to ≤ 90%)2
Packed (> 90% to ≤ 100%)0
Missing1

1 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • Celgene Clinical Site
    Shimono, Tochigi 329-0498, Japan
  • Celgene Clinical Site
    Shibuya-ku, Tokyo 150-8935, Japan
  • Celgene Clinical Site
    Hiroshima, 734-8551, Japan
  • Celgene Clinical Site
    Kyoto, 601-1495, Japan
  • Celgene Clinical Site
    Osaka, 543-8555, Japan
  • Celgene Clinical Site
    Shizuoka, 420-8527, Japan
09

References and documents

Publications

  • Matsuda A, Taniwaki M, Jinnai I, Harada H, Watanabe M, Suzuki K, Yanagita S, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Tohyama K, Takatoku M, Ozawa K. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study. Leuk Res. 2012 May;36(5):575-80. doi: 10.1016/j.leukres.2011.11.011. Epub 2011 Dec 15. PubMed 22172461 ↗
  • Harada H, Watanabe M, Suzuki K, Yanagita S, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Matsuda A, Tohyama K, Taniwaki M, Takeshita K, Takatoku M, Ozawa K. Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality. Int J Hematol. 2009 Oct;90(3):353-360. doi: 10.1007/s12185-009-0400-8. Epub 2009 Aug 25. PubMed 19705057 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2007 to primary completion in Sep 2010, 36 months.

Results were first posted in Dec 2013, 3 years 3 months after primary completion.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 36 months is close to that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2008
First posted
Dec 22, 2008
StartActual
Sep 1, 2007
Primary completionActual
Sep 1, 2010
CompletionActual
Sep 1, 2010
Results first posted
Dec 17, 2013
Last update
Nov 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00812968
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Dec 22, 2008
Start date
Sep 1, 2007
Primary completion
Sep 1, 2010
Completion
Sep 1, 2010
Results posted
Dec 17, 2013
Last update
Nov 19, 2019

Study contacts

Masaaki Takatoku, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion